From 'gills to pills': urotensin-II as a regulator of mammalian cardiorenal function

被引:135
作者
Douglas, SA
Dhanak, D
Johns, DG
机构
[1] GlaxoSmithKline, Cardiovasc & Urogenital Ctr Excellence Drug Disco, Dept Vasc Biol, King Of Prussia, PA 19406 USA
[2] GlaxoSmithKline, Microbial Musculoskeletal & Proliferat Dis Ctr Ex, Dept Oncol Chem, Collegeville, PA 19426 USA
关键词
D O I
10.1016/j.tips.2003.12.005
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The identification of a human homolog of urotensin-II (U-II) and a novel, specific G-protein-coupled receptor by Ames et al. in 1999 changed the perception that the U-II isopeptide family was an esoteric collection of 'somatostatin-like neuropeptides' present only in the nervous systems of an eclectic array of aquatic invertebrates, fish and amphibians. In this article, we review recent developments in the pharmacology of human U-II, focusing on the actions of this peptide in the mammalian cardiorenal system. The putative role of U-II in the etiology of hypertension, heart failure, renal dysfunction and diabetes is discussed, as are novel U-II receptor antagonists.
引用
收藏
页码:76 / 85
页数:10
相关论文
共 99 条
  • [1] Involvement of the nitric oxide/L-arginine and sympathetic nervous systems on the vasodepressor action of human urotensin II in anesthetized rats
    Abdelrahman, AM
    Pang, CCY
    [J]. LIFE SCIENCES, 2002, 71 (07) : 819 - 825
  • [2] No effect on central or peripheral blood pressure of systemic urotensin II infusion in humans
    Affolter, JT
    Newby, DE
    Wilkinson, IB
    Winter, MJ
    Balment, RJ
    Webb, DJ
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2002, 54 (06) : 617 - 621
  • [3] AISSAOUI H, 2002, Patent No. 0276979
  • [4] Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14
    Ames, RS
    Sarau, HM
    Chambers, JK
    Willette, RN
    Alyar, NV
    Romanic, AM
    Louden, CS
    Foley, JJ
    Sauermelch, CF
    Coatney, RW
    Ao, ZH
    Disa, J
    Holmes, SD
    Stadel, JM
    Martin, JD
    Liu, WS
    Glover, GI
    Wilson, S
    McNulty, DE
    Ellis, CE
    Elshourbagy, NA
    Shabon, U
    Trill, JJ
    Hay, DWP
    Ohlstein, EH
    Bergsma, DJ
    Douglas, SA
    [J]. NATURE, 1999, 401 (6750) : 282 - 286
  • [5] Pharmacological characterization of SB-710411 (Cpa-c[D-Cys-Pal-D-Trp-Lys-Val-Cys]-Cpa-amide), a novel peptidic urotensin-II receptor antagonist
    Behm, DJ
    Herold, CL
    Ohlstein, EH
    Knight, SD
    Dhanak, D
    Douglas, SA
    [J]. BRITISH JOURNAL OF PHARMACOLOGY, 2002, 137 (04) : 449 - 458
  • [6] Deletion of the UT receptor gene results in the selective loss of urotensin-II contractile activity in aortae isolated from UT receptor knockout mice
    Behm, DJ
    Harrison, SM
    Ao, ZH
    Maniscalco, K
    Pickering, SJ
    Grau, EV
    Woods, TN
    Coatney, RW
    Doe, CPA
    Willette, RN
    Johns, DG
    Douglas, SA
    [J]. BRITISH JOURNAL OF PHARMACOLOGY, 2003, 139 (02) : 464 - 472
  • [7] BENNETT T, 2002, BRIT J PHARMACOL, V135, P200
  • [8] Bern H.A., 1985, Recent Progress in Hormone Research, V41, P533
  • [9] Urotensin II evokes potent vasoconstriction in humans in vivo
    Böhm, F
    Pernow, J
    [J]. BRITISH JOURNAL OF PHARMACOLOGY, 2002, 135 (01) : 25 - 27
  • [10] Plasma concentrations of arginine vasotocin and urotensin II are reduced following transfer of the euryhaline flounder (Platichthys flesus) from seawater to fresh water
    Bond, H
    Winter, MJ
    Warne, JM
    McCrohan, CR
    Balment, RJ
    [J]. GENERAL AND COMPARATIVE ENDOCRINOLOGY, 2002, 125 (01) : 113 - 120